CN1562337A - Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method - Google Patents
Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method Download PDFInfo
- Publication number
- CN1562337A CN1562337A CNA200410021412XA CN200410021412A CN1562337A CN 1562337 A CN1562337 A CN 1562337A CN A200410021412X A CNA200410021412X A CN A200410021412XA CN 200410021412 A CN200410021412 A CN 200410021412A CN 1562337 A CN1562337 A CN 1562337A
- Authority
- CN
- China
- Prior art keywords
- kidney
- treatment
- insufficiency
- fructus
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title description 4
- 239000000463 material Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- 210000000582 semen Anatomy 0.000 claims description 38
- 239000000706 filtrate Substances 0.000 claims description 30
- 239000008187 granular material Substances 0.000 claims description 30
- 238000007654 immersion Methods 0.000 claims description 29
- 241000255783 Bombycidae Species 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 21
- 241000208340 Araliaceae Species 0.000 claims description 17
- 241000005787 Cistanche Species 0.000 claims description 17
- 241000190633 Cordyceps Species 0.000 claims description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 17
- 235000008434 ginseng Nutrition 0.000 claims description 17
- 210000001320 hippocampus Anatomy 0.000 claims description 17
- 239000002994 raw material Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 13
- 239000000470 constituent Substances 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- -1 filter Substances 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- 241000756943 Codonopsis Species 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 abstract description 23
- 230000007812 deficiency Effects 0.000 abstract description 10
- 201000001881 impotence Diseases 0.000 abstract description 5
- 208000002173 dizziness Diseases 0.000 abstract description 4
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 241000255789 Bombyx mori Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 29
- 235000019441 ethanol Nutrition 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 229960003604 testosterone Drugs 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010063659 Aversion Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000009205 Tinnitus Diseases 0.000 description 4
- 210000004100 adrenal gland Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 206010036596 premature ejaculation Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 231100000886 tinnitus Toxicity 0.000 description 4
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010024264 Lethargy Diseases 0.000 description 3
- 206010024642 Listless Diseases 0.000 description 3
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 231100001252 long-term toxicity Toxicity 0.000 description 3
- 206010029446 nocturia Diseases 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 3
- 229960002646 scopolamine Drugs 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241001051743 Eacles imperialis Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 230000033540 T cell apoptotic process Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043949 Tongue discolouration Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008929 jingui shenqi Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002863 seminiferous tubule Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A Chinese medicine for treating senile weakness, deficiency of kidney's vital function, impotence, emission, ejaculation praecox, dizziness, etc is prepared from 13 Chinese-medicinal materials including red ginseng, male silkworm moth, wolfberry fruit, mulberry fruit, etc.
Description
Technical field
The present invention relates to a kind of Chinese medicine for the treatment of nephropathy, relate in particular to the Chinese medicine and preparation method thereof that a kind of QI invigorating is added the treatment insufficiency of kidney-YANG of essence, kidney-reinforcing Yang-strengthening.
Background technology
Along with population middle-aged and elderly people ratio rises gradually, old and feeble with how slow down aging has become the world of medicine's question of common concern.The many duties of old and feeble and relevant disease with aging in kidney, suffering from a deficiency of the kidney is a kind of multiple difficult disease, is a difficult problem that perplexs medical circle, decline for seeing with kidney yang (void) especially in the nephropathy more, also be the basic reason that makes people's aging and suffer from a deficiency of the kidney.There is investigation to show that the old people of China about 70% is partial to insufficiency of kidney-YANG.People in middle age, physiological function begins to descend, and is the important stage of prevention and slow down aging.The kidney being the origin of congenital constitution, and kidney yang is easily empty, thus see impotence due to deficiency of the kidney, the seminal emission premature ejaculation, fatigue and weakness forgetful dusk such as being had a liking for.If can strengthen this moment the taking good care of of kidney, slow down aging and medical care for the aged health care are had the important clinical meaning.
At the Western medicine that is used for preventing and treating aging, major part is a hormone medicine at present, and side effect is bigger, can separate needing of a period of time, but life-time service has dependency, cures the symptoms, not the disease.The Chinese medicine the kidney invigorating can integrally-regulated human nerve, endocrine and immune system, delay with age and the T Lymphocyte Apoptosis quickened, and the gene expression of the old and feeble inherited characteristic of influence reflection.
Existing prevention and the old and feeble Chinese patent medicine of treatment though as JINGUI SHENQI WAN, kidney tonifying sheet, YANSHENG HUBAO YE etc. certain curative effect is arranged, act on not obviously, can not carry out Comprehensive Treatment to suffering from a deficiency of the kidney, and the course of treatment are long, the actual therapeutic poor effect.
Contain this Chinese crude drug composition of male Bombycis mori in the Chinese medicine that some treatment is suffered from a deficiency of the kidney, because male Bombycis mori oiliness, gas raw meat, salty in the mouth, the preparation mouthfeel that causes containing this medicine is relatively poor.
Summary of the invention
Technical problem to be solved by this invention is Chinese medicine of the treatment insufficiency of kidney-YANG that provides at the problems referred to above and preparation method thereof, the present invention has short treating period, instant effect, nontoxic, side effect, characteristics such as therapeutic effect is remarkable, the present invention is used as medicine after earlier male Bombycis mori being processed, and has alleviated the bad smell that male Bombycis mori directly is used as medicine.
The weight ratio scope of each raw material of the present invention be through the inventor carry out a large amount of grope to sum up with experimentation draw, the weight ratio of each raw material all has curative effect preferably in following weight range, the present invention adopts following 13 kinds of medicines to make up, make each efficacy of drugs produce synergism these drug regimens, thereby effectively prevention and slow down aging, treatment are suffered from a deficiency of the kidney.
In order to address the above problem, the present invention is achieved in that it is to be made of by weight following raw material:
Radix Ginseng Rubra: male Bombycis mori: Herba Epimedii (system): Fructus Lycii: Fructus Mori: Herba Cistanches (system): Semen Juglandis: Fructus Schisandrae Chinensis: Gecko: Hippocampus: Cordyceps: Radix Polygoni Multiflori Preparata: Semen Astragali Complanati=(220-280): (390-445): (390-445): (390-445): (390-445): (220-280): (130-190): (100-170): (120-190): (35-70): (35-70): (220-280): (220-280).
The present invention can adopt the conventional method of Chinese medicine preparation to make any conventional oral formulations, as dosage forms such as tablet, capsule, powder, granule, oral liquid, syrup, Emulsion, suspensoids.
Its preparation method may further comprise the steps:
(1). get the airtight steeping in wine of male Bombycis mori by above-mentioned weight ratio, filter, decompression filtrate recycling ethanol gets the male silkworm moths spirit immersion;
(2). add cyclodextrin in above-mentioned male silkworm moths spirit immersion, the male silkworm moths spirit immersion is with the cyclodextrin mixing and make into the enclose state, gets male silkworm moths spirit immersion clathrate, and drying is pulverized, and gets fine powder A;
(3). get Radix Ginseng Rubra, Cordyceps, Fructus Lycii, Semen Juglandis, Fructus Schisandrae Chinensis, Radix Polygoni Multiflori Preparata, Gecko, Herba Cistanches (system), Hippocampus by above-mentioned weight ratio, alcohol extraction, merge extractive liquid, filters, and gets liquor C;
(4). get Fructus Mori, Herba Epimedii (system), Semen Astragali Complanati by above-mentioned weight ratio and decoct with water, filter, filtrate D, be concentrated into clear paste, cooling adds ethanol, stir, leave standstill, filter, get filtrate F, filtrate F and C are merged, reclaim ethanol and be concentrated into thick paste, be dried to dried cream, dried cream powder is broken, get fine powder B;
(5). two kinds of fine powders mixing of above-mentioned A, B had both been got active constituents of medicine of the present invention.
Last medicinal residues mix in the time of will getting liquor C and filtrate D in above-mentioned (3) step and (4) step, decoct with water, and get filtrate E, and filtrate D and E are merged, and carry out downwards by described in (4).
Active constituents of medicine in the above-mentioned step (5) adds the granule right amount of auxiliary materials, and mixing is granulated, and drying promptly gets granule.
Add solid preparation common dosage forms adjuvant in the active constituents of medicine in the above-mentioned step (5) and mix, technology is made tablet routinely, also can not add adjuvant and directly active constituents of medicine be made tablet.
After fine powder A, B in the above-mentioned step (5) mix, add lubricant or do not add, incapsulate, capsule.
Add 60%-85%% alcohol reflux secondary in above-mentioned (3) step, add 10 times of amounts for the first time, extracted 2 hours, add 8 times of amounts for the second time, extracted 2 hours, merge extracted twice liquid.
The weight ratio of each raw material of the present invention is:
Radix Ginseng Rubra: male Bombycis mori: Herba Epimedii (system): Fructus Lycii: Fructus Mori: Herba Cistanches (system): Semen Juglandis: Fructus Schisandrae Chinensis: Gecko: Hippocampus: Cordyceps: Radix Polygoni Multiflori Preparata: Semen Astragali Complanati=240: 407: 417: 417: 427: 260: 163: 139: 170: 45: 45: 235: 235.
Above-mentioned Radix Ginseng Rubra can use Radix Panacis Quinquefolii, Radix Codonopsis, Radix Pseudostellariae to replace; The available Radix Morindae Officinalis of Herba Epimedii (system), Rhizoma Curculiginis replace; The available Cornu Cervi Pantotrichum of Herba Cistanches (system) replaces; Semen Astragali Complanati can be used Semen Cuscutae.
Advantage of the present invention and effect are as follows: the present invention is a kidney invigorating class pure Chinese medicinal preparation, can integrally-regulated human nerve, endocrine and immune system, delay with age and the T Lymphocyte Apoptosis quickened, and the gene expression of the old and feeble inherited characteristic of influence reflection.Cure mainly old asthenia, body void after being ill, impotence due to deficiency of the kidney, the seminal emission premature ejaculation, soreness of the waist and knees, aversion to cold and cold limbs, fatigue and weakness, vertigo and tinnitus, dribble of urine are not to the greatest extent, have a liking for forgetful dusk etc., have short treating period, instant effect is nontoxic, side effect, treating both the principal and secondary aspects of a disease, advantages such as therapeutic effect is remarkable, thus reached the effect of life lengthening, and the present invention simultaneously can also reduce oxygen consumption, increase heart to anoxybiotic tolerance, have remarkable brain strengthening function, also can improve the resistance against diseases of body, the present invention has adopted the technology of being used as medicine behind " male Bombycis mori " first enclose, the bad smell of having avoided male Bombycis mori directly to be used as medicine can be accepted this agent by the patient on mouthfeel.
The specific embodiment
Below routine by experiment beneficial effect of further setting forth medicine of the present invention, these experiments comprise pharmacodynamic experiment, long term toxicity test and clinical trial.
(experimental example one)
Long-term toxicity test for animals
Granule rat long term toxicity test of the present invention is divided into four groups, large, medium and small dosage and matched group, and 20 every group, male and female half and half, successive administration 2 months is put to death then.10 of heavy dose of groups, in, low dose and matched group all put to death, and does the pathology inspection.Heavy dose of 10 in addition of organizing stop administration and normally raise the same processing of two weeks, also do the pathology inspection, observe its result.
One, censorship material: the rat heart, liver, spleen, lung, kidney, brain, adrenal gland and testis (ovary) tissue.
Two, censorship purpose: observe the toxic action of granule of the present invention, observe variations such as its tissue to the rat heart, liver, spleen, lung, kidney, brain, adrenal gland and testis (ovary).
Totally 80 examples are organized in censorship, and dislocation is put to death rat and removed internal organs, conventional fixing (10% formalin) paraffin section, HE dyeing, light microscopy checking.
Three, finding is described below by various dose under the mirror:
1, heavy dose of group: totally 20, wherein preceding 10 visible livers have in the 2 routine sinus hepaticus and are full of erythrocyte, are the congestion shape, and hepatocyte does not see significant change; Visible inflammatory cell infiltration in the matter is the lobule class and changes between lungs 2 examples, and visible most erythrocyte in the 1 routine alveolar space are arranged, and is hemorrhage shape; Kidney has and is full of erythrocyte between 1 example in the matter, is congested shape and changes.Back 10 examples wherein liver have 3 examples to be the congestion shape; The visible hemorrhage and interstitial inflammation of lungs sexually revises, other organize heart-myocardial cell and between matter, spleen-blood marrow and red pulp, brain-grey matter and blood vessel, each cell of testis-spermatogenic epithelium and between matter and adrenal gland there is no obvious change.
2, middle dosage group: totally 20 examples, wherein liver has in the 4 routine sinus hepaticus and is the congestion shape, lungs also as seen, hemorrhage and interstitial inflammation sexually revises, other tissue shows no obvious abnormalities change.
3, small dose group: totally 20 examples, its cardiac have between 1 example the matter blood vessel be full of erythrocyte to be hemorrhage shape, and congestion that the change of liver and liver is all identical with big or middle dosage group and inflammatory change.
Small dose group has spermatogenic cell disappearance in the visible convoluted seminiferous tubule of 1 routine testis tissue, only visible a little sustenticular cell, and other tissue there is no obvious change.
Four, brief summary
The congestion of all visible liver of each dosage group of granule of the present invention, the hemorrhage and inflammatory of lungs changes, no dose-response relationship, the real animal id reaction that belongs to, and it is improper and cause with this empirical factor and have nothing to do to put to death animal.
2,1 routine heart and the congested no pathology meaning of 1 routine kidney
3, wherein small dose group only has 1 routine testis generation degeneration, and routine number is less, wouldn't illustrate relevant with this empirical factor, may be relevant age with Mus, be a kind of senile change.
4, granule of the present invention does not see that to each internal organs of rat (heart, liver, spleen, lung, kidney, brain, adrenal gland and testis) toxicity changes.
(experimental example two)
Clinical research
Granule of the present invention is the pure Chinese medicinal preparation of Shengang Dongling Medicine Inst development.Be the clinical efficacy of definite granule of the present invention and the safety of its use of observation, defend (94) No. 113 documentation requirements of medicine letter word according to the Liao Dynasty of Department of Public Health of Shanxi Province, unite by Liaoning Prov. Traditional Chinese Medicine Inst, General Hospital of Shenyang Railway Bureau and Liaoning People's Hospital and carry out 100 routine clinical observation on the therapeutic effect.Now the observed result comprehensive report is as follows.
The case source is the male for selecting to meet the door rash and the inpatient of syndrome of deficiency of kidney-YANG diagnosis at random, observation group's (granule of the present invention) 100 examples, 47.23 ± 8.05 years old mean age, minimum 29 years old, maximum 64 years old; Average course of disease 2.08 ± 1.24 years, the shortest 0.33, the longest 6 years; Severity extent before the treatment is investigated with average symptom integral, is 26.53 ± 6.47 minutes.Matched group 60 examples, 48.5 ± 9.19 years old mean age, minimum 30 years old, maximum 63 years old; Average course of disease 2.04 ± 1.18 years, the shortest 0.25, the longest 4.67 years; Average symptom integral 24.57 ± 6.69 minutes (seeing table 1 for details) before the treatment.Observation group and matched group patient are at age, the course of disease and the state of an illness (symptom integral value before the treatment) aspects, and difference that there are no significant by analysis (P＞0.05) points out two groups to have harmony and comparability.
The harmonious table of measuring of table 1 observation group and matched group
The average state of an illness of example number
Group P value P value P value
The out-patient clinic and hospitalization age course of disease (average symptom integral)
Observation group 70 30 47.23 ± 8.05 2.08 ± 1.24 26.53 ± 6.47
＞0.05 ＞0.05 ＞0.05
Matched group 60 48.5 ± 9.19 2.04 ± 1.18 24.57 ± 6.69
One, experimental technique
By table of random number, tell observation group's 100 example and matched group 60 examples at random.
Medication administration method: one bag of granule of the present invention (being provided by the Shengang Dongling Medicine Inst) a time, three times on the one oral, observes a course of treatment (4 week).Matched group 60 examples, contrast medicine be YANSHENG HUBAO YE (Shenyang flying dragon Medicines and Health Product group produces, lot number: 940316), a 20ml, once-a-day, sleep preceding 2 hours oral, observed for 4 weeks.All cases that is included into two groups are filled in unified case history observation table by full-time doctor, and other relevant kidney invigorating and YANG supporting medicine (containing Chinese medicine, Western medicine) all should be withdrawn with matched group by observation group.
Two, significance test
According to the requirement of this programme design, enumeration data is intended X with observation index
2Carry out significance test, measurement data is intended carrying out the T significance test.
Three, clinical observation result
(1) observation group and matched group curative effect are relatively
As shown in Table 2, observation group's produce effects 51 examples, effective 43 examples.Obvious effective rate is 51%, total effective rate 94%.Matched group produce effects 30 examples, effective 26 examples, obvious effective rate is 50%, total effective rate is 93.3%.Through X
2Check, two groups of treatment back obvious effective rates and total effective rate there are no significant difference, P＞0.05. to observation group and treatment of control group after comparison shows that of symptom integral value, after the treatment, observation group dropped to 10.02 ± 5.75 fens by 20.33 ± 4.29 minutes, and matched group dropped to 8.58 ± 4.74 fens by 18.93 ± 2.68 minutes, through check, two groups of treatment back symptom integral value differences are different not remarkable, P＞0.05 (seeing Table 3)
Table 2 observation group and matched group curative effect are relatively
Produce effects enabledisable obvious effective rate % total effective rate % P value
Group example number
Example (%) example (%) example (%)
Observation group 100 51 (51) 43 (43) 6 (6) 51 94
＞0.05
Matched group 60 30 (50) 26 (43.3) 4 (6.7) 50 93.3
The symptom integral value relatively after table 3 observation group and the treatment of control group
Treatment back symptom integral value
Group example number P value
(X±SD)
Observation group 100 10.02 ± 5.75
＞0.05
Matched group 60 8.58 ± 4.74
(2) clinical each the symptom curative effect of observation group and matched group relatively
The disease that syndrome of deficiency of kidney-YANG is seen in of observation group and treatment of control group is carried out curative effect relatively, and only lethargy symptom matched group is better than observation group (P＜0.05), the curative effect of all the other primary and secondary symptoms, difference that there are no significant between two groups (P＞0.05).The symptom integral value relatively before and after observation group's treatment, all symptoms all have significantly and significant difference (P＜0.05 or P＜0.001) extremely, particularly primary symptom shape such as soreness of the waist and knees, aversion to cold and cold limbs and indolent and listless weak, nocturia, dizzy, tinnitus grade symptom are improved significantly and therapeutical effect.
The clinical all symptom curative effects of table 4 observation group and matched group relatively
Observation of symptoms group matched group
Average integral after average product was divided and ruled before average integral example number was controlled after average product was divided and ruled before routine number was controlled
Soreness of the waist and knees 100 4.84 ± 1.24 1.61 ± 1.14 60 5.47 ± 0.89 1.78 ± 1.24
Aversion to cold and cold limbs 97 4.12 ± 1.24 1.19 ± 1.19 56 4.29 ± 1.17 1.29 ± 1.22
Appearance floating empty 53 3.30 ± 1.61 0.85 ± 1.22 12 2 ± 0 0.83 ± 0.94
Impotence and seminal emission premature ejaculation 74 3.61 ± 1.89 2.11 ± 1.36 32 3.31 ± 1.20 1.78 ± 1.13
Indolent and listless weak 96 2.17 ± 0.64 0.59 ± 0.66 58 2.52 ± 0.60 0.45 ± 0.68
Nocturia 68 1.88 ± 0.66 0.63 ± 0.67 33 2.18 ± 0.68 0.61 ± 0.83
Dribble of urine 42 1.76 ± 0.69 0.57 ± 0.59 29 1.93 ± 0.80 0.59 ± 0.68
Dizzy 52 1.62 ± 0.75 0.54 ± 0.64 17 1.71 ± 0.69 0.29 ± 0.47
Tinnitus 70 1.81 ± 0.77 0.64 ± 0.61 37 1.76 ± 0.64 0.46 ± 0.56
Forgetful 75 1.76 ± 0.75 0.8 ± 0.70 37 1.78 ± 0.67 0.65 ± 0.54
Lethargy 33 2 ± 0.61 0.73 ± 0.76 23 2.04 ± 0.64 0.30 ± 0.56
Light red tongue fat 82 1.87 ± 0.49 1.13 ± 0.72 32 2.66 ± 0.60 1.44 ± 1.01
Tongue white 84 1.49 ± 0.55 0.73 ± 0.80 49 1.92 ± 0.89 0.78 ± 0.90
Deep-thready pulse or slow weak 98 1.64 ± 0.54 0.95 ± 0.66 57 1.95 ± 0.93 1.19 ± 1.09
Treatment back observation group and matched group be P＜0.05 relatively
(3) observation group's course of disease and therapeutic effect relationship are relatively
As shown in Table 5, in observation group's 100 examples, 3～6 months 2 people of the course of disease, 6～12 months 13 people, 1～3 year 61 people, 24 people more than 3 years.Total effective rate is respectively 100%, 100%, and 95.1% and 87.5%.Analyze through Ridit, all do not have produce effects difference between each course of disease patient's the curative effect, P＞0.05.
The table 5 observation group course of disease and therapeutic effect relationship are relatively
Group example digital display is imitated enabledisable total effective rate % P value
Example % example % example %
February above 21 (50) 1 (50) 100
Half a year above 13 7 (53.8) 6 (46.2) 100
＞0.05
More than 1 year 61 33 (54.1) 25 (41.0) 3 (4.9) 95.1
More than 3 years 24 10 (41.7) 11 (45.8) 3 (12.5) 87.5
(4) variation of serum testosterone content before and after observation group's treatment
The 30 routine patients of observation group have been carried out the twice serum testosterone Determination on content in treatment front and back, the result shows, treatment through a course of treatment, the serum testosterone is by the 405.08 ± 306.2ng/dl that treats after 258.02 preceding ± 232.76ng/dl rises to treatment, serum testosterone content has extremely significant difference, P＜0.001 before and after the treatment.This promptly points out, and granule of the present invention has the effect of rising serum testosterone content.
Serum testosterone changes of contents relatively before and after the treatment of table 8 observation group
Treatment back P value before the treatment of example number
30 258.02±232.76ng/dl 405.08±306.02ng/dl ＜0.001
Four, conclusion
Clinical observation result proves, granule of the present invention is not most, dizzy to the floating void of insufficiency of kidney-YANG finding soreness of the waist and knees, aversion to cold and cold limbs, appearance, sexual impotence, seminal emission, premature ejaculation and indolent and listless weak, nocturia, dribble of urine, tinnitus, lethargy etc. have better prevention and therapeutical effect, determined curative effect, and certain adjusting male hormone metabolism level arranged, having no side effect, is a kind of pure Chinese medicinal preparation of taking convenience.
(experimental example three)
Cure mainly relevant Pharmacodynamic test of active extract with function
One, experiment material
Granule of the present invention is provided by the Shengang Dongling Medicine Inst, and experiment is to carry out with the medicine that does not add excipient.
Dragon moth liquid longevity Dandong City east star pharmaceutical factory product batch number: 930301
Scopolamine Switzerland makes lot number: 136330
Rat, the supply of mice Liaoning Province institute of materia medica animal housing
Two, experiment and result
Granule of the present invention is to the influence of scopolamine induced mice memory acquisition disturbance, and body weight 18～22 restrains 95 of Kunming mouses, and male and female half and half are divided into five groups at random, 19 every group.Two groups of mouse gavaging co-content normal saline.Three groups gavage imperial moth liquid longevity 8.0ml/kg respectively in addition, granule 37.0 of the present invention and 18.5g/kg (crude drug), once a day, serve on 10 days, after the last administration 50 minutes, except that one group of normal saline group (blank), another group normal saline group (model group) and three administration group mices.
Three, brief summary
Originally experiment showed, that (1) granule of the present invention can significantly increase the sexual behaviour of castration mouse; (2) significantly increase the growth of castration mouse gonad organ, present the effect of androgen sample; (3) can obviously increase the sexual behaviour of rat, make to catch and obviously shorten when hiding, significantly increase and catch number of times, increase copulation and ejaculation frequency, prove that granule of the present invention has significant life essence-filling, marrow-benefitting, the effect of kidney invigorating and YANG supporting, its effect obviously are better than contrast medicine dragon moth liquid longevity.
The experiment proved that, granule of the present invention is to the mice of memory acquisition disturbance due to the scopolamine, in the time of significantly shortening the hiding of diving tower experiment of mice, obviously reduce errors number and significantly shorten the time of being shocked by electricity, show the effect that remarkable hypermnesis is arranged, and obviously be better than contrast medicine dragon moth liquid longevity.Experiment is proof also, and granule of the present invention can significantly tolerate the acute brain anoxia.The mice oxygen metabolism experiment showed, that this medicine can reduce oxygen consumption, increases heart to anoxybiotic tolerance, above-mentioned experiment as can be seen, granule of the present invention has remarkable brain strengthening function.
Experiment is proof also, and castration mouse is seriously lacked of proper care because of androgen, will influence organism endocrine metabolism and protein assimilation, makes body weight gain slow, but this medicine can obviously increase the growth of castration mouse body weight, obviously is better than normal saline and imperial moth liquid longevity.This medicine can obviously increase phagocytic index, increases liver, spleen, thymic weight, and showing has the effect that increases non-specific immunity, can improve the resistance against diseases of body.Experiment proves that also this medicine can increase mice pole-climbing endurance and swimming time reaches more than one times.These experiments illustrate that all this medical instrument has significant strong effect.
" embodiment one " raw material of the present invention constitutes and it is prepared into the technology of granule
A kind of Chinese medicine for the treatment of insufficiency of kidney-YANG of the present invention is to be made of by weight following raw material:
Radix Ginseng Rubra: male Bombycis mori: Herba Epimedii (system): Fructus Lycii: Fructus Mori: Herba Cistanches (system): Semen Juglandis: Fructus Schisandrae Chinensis: Gecko: Hippocampus: Cordyceps: Radix Polygoni Multiflori Preparata: Semen Astragali Complanati=240: 407: 417: 417: 427: 260: 163: 139: 170: 45: 45: 235: 235;
Its method that is prepared into granule is comprised the steps:
(1). get male Bombycis mori by above-mentioned weight ratio and add the 50 degree Chinese liquor airtight immersions of 6 times of amounts, filter, filtrate is in 0.1Mpa, 45 ℃ of decompression recycling ethanols, the male silkworm moths spirit immersion, to the male silkworm moths spirit immersion be every milliliter of solution that contains the 2g crude drug;
(2). in above-mentioned male silkworm moths spirit immersion, add beta-schardinger dextrin-, the consumption ratio of beta-schardinger dextrin-and male silkworm moths spirit immersion is 1: 1, with beta-schardinger dextrin-and male silkworm moths spirit immersion mixing, grinds, use mortar in a small amount, ground 2 hours down with room temperature such as ball mill or colloid mill, refiner, high-shearing dispersion emulsifying machines slightly in a large number, high-shearing dispersion emulsifying machine got final product in 15 minutes, get final product male silkworm moths spirit immersion clathrate, at 60 ℃ of vacuum dryings, pulverize, cross 80 mesh sieves, get fine powder A;
(3). get Radix Ginseng Rubra, Cordyceps, Fructus Lycii, Semen Juglandis, Fructus Schisandrae Chinensis, Radix Polygoni Multiflori Preparata, Gecko, Herba Cistanches (system), Hippocampus by above-mentioned weight ratio, add 65% alcohol reflux secondary, add for the first time 10 times of amounts, extracted 2 hours, for the second time add 8 times of amounts, extracted 2 hours, merge extracted twice liquid, filter, get liquor C;
(4). get after Fructus Mori, Herba Epimedii (system), Semen Astragali Complanati add 15 times of amounts of water and soak 8 hours by above-mentioned weight ratio, decocted 2 hours, filter, must filtrate D, being concentrated into relative density is the clear paste of 1.0 (70 ℃), is chilled to room temperature, adds ethanol, make to contain alcohol amount and reach 70%, fully stir, leave standstill, filter, get filtrate F, filtrate F and C are merged, reclaim ethanol and be concentrated into thick paste, become dried cream in 80 ℃ of following vacuum dryings, dried cream powder is broken, cross 130 mesh sieves, get fine powder B, standby;
(5). two kinds of fine powders of above-mentioned A, B are mixed, get active constituents of medicine of the present invention;
(6). add steviosin in active component of the present invention, cane sugar powder is an amount of, mixing is granulated with 6% hydroxypropyl emthylcellulose alcoholic solution, and 60 ℃ of dryings promptly get granule.
" embodiment two " raw material of the present invention constitutes and it is prepared into the technology of granule
A kind of Chinese medicine for the treatment of insufficiency of kidney-YANG of the present invention is to be made of by weight following raw material: Radix Pseudostellariae: male Bombycis mori: Herba Epimedii (system): Fructus Lycii: Fructus Mori: Herba Cistanches (system): Semen Juglandis: Fructus Schisandrae Chinensis: Gecko: Hippocampus: Cordyceps: Radix Polygoni Multiflori Preparata: Semen Astragali Complanati=220: 390: 390: 390: 390: 220: 130: 100: 120: 35: 35: 220: 220;
Its method that is prepared into granule is comprised the steps:
(1). get male Bombycis mori by above-mentioned weight ratio and add the airtight immersion of 10 times of amount Chinese liquor (80 degree), filter, filtrate is in 0.15Mpa, 50 ℃ of decompression recycling ethanols, the male silkworm moths spirit immersion, to the male silkworm moths spirit immersion be every milliliter of solution that contains the 0.5g crude drug;
(2). add gamma-cyclodextrin in above-mentioned male silkworm moths spirit immersion, the consumption ratio of male silkworm moths spirit immersion and gamma-cyclodextrin is 1: 2, with male silkworm moths spirit immersion and beta-schardinger dextrin-mixing, homogenate, get final product male silkworm moths spirit immersion clathrate, 65 ℃ of vacuum dryings are pulverized, cross 120 mesh sieves, get fine powder A;
(3). get Radix Ginseng Rubra, Cordyceps, Fructus Lycii, Semen Juglandis, Fructus Schisandrae Chinensis, Radix Polygoni Multiflori Preparata, Gecko, Herba Cistanches (system), Hippocampus by above-mentioned weight ratio, add 80% alcohol reflux secondary, add for the first time 12 times of amounts, extracted 2 hours, for the second time add 9 times of amounts, extracted 2 hours, merge extracted twice liquid, filter, it is standby to get liquor C and medicinal residues;
(4). get after Fructus Mori, Herba Epimedii (system), Semen Astragali Complanati add 10 times of amounts of water and soak 12 hours by above-mentioned weight ratio, decocted 3 hours, filter, must filtrate D and medicinal residues; With these medicinal residues and in (3) step the medicinal residues of gained mix, decoct with water 3 hours, filter, filtrate E, filtrate D and E are merged, and being concentrated into relative density is the clear paste of 0.9 (70 ℃), is chilled to room temperature, adds ethanol, make to contain alcohol amount and reach 55%, fully stir, leave standstill, filter, get filtrate F, filtrate F and C are merged, reclaim ethanol and be concentrated into thick paste, become dried cream in 80 ℃ of following vacuum dryings, dried cream powder is broken, cross 70 mesh sieves, get fine powder B, standby;
(5). two kinds of fine powders of above-mentioned A, B are mixed, get active constituents of medicine of the present invention;
(6). add steviosin in active component of the present invention, lactose is an amount of, mixing is done binding agent with 8% hydroxypropyl emthylcellulose alcoholic solution, granulate, 60 ℃ of dryings, packing promptly gets granule.Wherein lactose can be replaced by similar medicine such as glucose, dextrin, mannitol.
" embodiment three " raw material of the present invention constitutes and it is prepared into the technology of capsule
A kind of Chinese medicine for the treatment of insufficiency of kidney-YANG of the present invention is to be made of by weight following raw material: Radix Panacis Quinquefolii or Radix Codonopsis: male Bombycis mori: Herba Epimedii (system): Fructus Lycii: Fructus Mori: Cornu Cervi Pantotrichum: Semen Juglandis: Fructus Schisandrae Chinensis: Gecko: Hippocampus: Cordyceps: Radix Polygoni Multiflori Preparata: Semen Cuscutae=280: 445: 445: 445: 445: 280: 190: 170: 190: 70: 70: 280: 280;
Its technology that is prepared into capsule is comprised the steps:
(1). get male Bombycis mori by above-mentioned weight ratio and add the Chinese liquor airtight immersion of 3 times of amounts, filter, filtrate is in 0.1Mpa, 35 ℃ of decompression recycling ethanols, to the male silkworm moths spirit immersion be every milliliter of male silkworm moths spirit immersion that contains the 4g crude drug;
(2). add alpha-cyclodextrin in above-mentioned male silkworm moths spirit immersion, the consumption ratio of male silkworm moths spirit immersion and alpha-cyclodextrin is 1: 0.5, with male silkworm moths spirit immersion and alpha-cyclodextrin mixing, homogenate gets male silkworm moths spirit immersion clathrate, at 55 ℃ of following vacuum dryings, pulverize, cross 70 mesh sieves, get fine powder A;
(3). get Radix Ginseng Rubra, Cordyceps, Fructus Lycii, Semen Juglandis, Fructus Schisandrae Chinensis, Radix Polygoni Multiflori Preparata, Gecko, Herba Cistanches (system), Hippocampus by above-mentioned weight ratio, add 75% alcohol reflux secondary, add for the first time 8 times of amounts, extracted 3 hours, for the second time add 9 times of amounts, extracted 2 hours, merge extracted twice liquid, filter, it is standby to get liquor C and medicinal residues;
(4). get after Fructus Mori, Herba Epimedii (system), Semen Astragali Complanati add 20 times of amounts of water and soak 6 hours by above-mentioned weight ratio, decocted 2 hours, filter, must filtrate D and medicinal residues; With these medicinal residues and in (3) step the medicinal residues of gained mix, decoct with water 1 hour, filter, filtrate E, filtrate D and E are merged, and being concentrated into relative density is the clear paste of 1.1 (70 ℃), is chilled to 8 ℃, adds ethanol, make to contain alcohol amount and reach 70%, fully stir, leave standstill, filter, get filtrate F, filtrate F and C are merged, reclaim ethanol and be concentrated into thick paste, become dried cream in 80 ℃ of following vacuum dryings, dried cream powder is broken, cross 90 mesh sieves, get fine powder B, standby;
(5). will directly incapsulate after two kinds of fine powders mixing of above-mentioned A, B, get capsule.
To also can add the agent of capsule traditional lubrication after two kinds of fine powders mixing of A, B in above-mentioned (5) step, in incapsulating then.
" embodiment four "
After two kinds of fine powders mixing of A, B in the embodiment one described step (5), mix with tablet adjuvant commonly used, tabletting had both got medicinal tablet of the present invention, and other is with embodiment one; The conventional adjuvant that wherein prepares tablet can be any one in the similar medicines such as lactose, glucose, starch, dextrin, mannitol.
" embodiment five "
The present invention is made of by weight following raw material:
Radix Ginseng Rubra: male Bombycis mori: Herba Epimedii (system): Fructus Lycii: Fructus Mori: Herba Cistanches (system): Semen Juglandis: Fructus Schisandrae Chinensis: Gecko: Hippocampus: Cordyceps: Radix Polygoni Multiflori Preparata: Semen Astragali Complanati=250: 417: 420g, 440: 427: 260: 180: 141: 170: 45: 55: 245: 235.
Preparation method is with embodiment one.
" embodiment six "
The present invention is made of by weight following raw material:
Radix Ginseng Rubra: male Bombycis mori: Radix Morindae Officinalis: Fructus Lycii: Fructus Mori: Cornu Cervi Pantotrichum: Semen Juglandis: Fructus Schisandrae Chinensis: Gecko: Hippocampus: Cordyceps: Radix Polygoni Multiflori Preparata: Semen Astragali Complanati=220: 445: 395: 445: 420: 220: 140: 100: 140: 50: 70: 270: 230;
Preparation method is with embodiment one.
" embodiment seven "
The present invention is made of by weight following raw material:
Radix Ginseng Rubra: male Bombycis mori: Rhizoma Curculiginis: Fructus Lycii: Fructus Mori: Herba Cistanches (system): Semen Juglandis: Fructus Schisandrae Chinensis: Gecko: Hippocampus: Cordyceps: Radix Polygoni Multiflori Preparata: Semen Astragali Complanati=235: 410: 395: 400: 415: 235: 169: 120: 140: 50: 45: 265: 215;
Preparation method is with embodiment two.
" embodiment eight "
The present invention is made of by weight following raw material:
Radix Ginseng Rubra: male Bombycis mori: Herba Epimedii (system): Fructus Lycii: Fructus Mori: Herba Cistanches (system): Semen Juglandis: Fructus Schisandrae Chinensis: Gecko: Hippocampus: Cordyceps: Radix Polygoni Multiflori Preparata: Semen Astragali Complanati=260: 425: 415: 425: 420: 255: 175: 155: 160: 60: 55: 270: 260;
Preparation method is with embodiment three.
Claims (10)
1. Chinese medicine for the treatment of insufficiency of kidney-YANG, it is characterized in that it is to be made of Radix Ginseng Rubra by weight following raw material: male Bombycis mori: Herba Epimedii (system): Fructus Lycii: Fructus Mori: Herba Cistanches (system): Semen Juglandis: Fructus Schisandrae Chinensis: Gecko: Hippocampus: Cordyceps: Radix Polygoni Multiflori Preparata: Semen Astragali Complanati=(220-280): (390-445): (390-445): (390-445): (390-445): (220-280): (130-190): (100-170): (120-190): (35-70): (35-70): (220-280): (220-280).
2. a kind of Chinese medicine for the treatment of insufficiency of kidney-YANG according to claim 1, the weight proportion that it is characterized in that its each raw material is a Radix Ginseng Rubra: male Bombycis mori: Herba Epimedii (system): Fructus Lycii: Fructus Mori: Herba Cistanches (system): Semen Juglandis: Fructus Schisandrae Chinensis: Gecko: Hippocampus: Cordyceps: Radix Polygoni Multiflori Preparata: Semen Astragali Complanati=240: 407: 417: 417: 427: 260: 163: 139: 170: 45: 45: 235: 235.
3. a kind of Chinese medicine for the treatment of insufficiency of kidney-YANG according to claim 1 and 2 is characterized in that described Radix Ginseng Rubra can use Radix Panacis Quinquefolii, Radix Codonopsis, Radix Pseudostellariae to replace; The available Radix Morindae Officinalis of Herba Epimedii (system), Rhizoma Curculiginis replace.
4. a kind of Chinese medicine for the treatment of insufficiency of kidney-YANG according to claim 1 and 2 is characterized in that the available Cornu Cervi Pantotrichum of described Herba Cistanches (system) replaces; Semen Astragali Complanati can replace with Semen Cuscutae; Fructus Lycii can replace with Fructus Ligustri Lucidi.
5. preparation method of Chinese medicine for the treatment of insufficiency of kidney-YANG, it is characterized in that it is to be made of Radix Ginseng Rubra by weight following raw material: male Bombycis mori: Herba Epimedii (system): Fructus Lycii: Fructus Mori: Herba Cistanches (system): Semen Juglandis: Fructus Schisandrae Chinensis: Gecko: Hippocampus: Cordyceps: Radix Polygoni Multiflori Preparata: Semen Astragali Complanati=(220-280): (390-445): (390-445): (390-445): (390-445): (220-280): (130-190): (100-170): (120-190): (35-70): (35-70): (220-280): (220-280);
Its preparation method may further comprise the steps:
(1). get the airtight steeping in wine of male Bombycis mori by above-mentioned weight ratio, filter, decompression filtrate recycling ethanol gets the male silkworm moths spirit immersion;
(2). add cyclodextrin in above-mentioned male silkworm moths spirit immersion, the male silkworm moths spirit immersion is with the cyclodextrin mixing and make into the enclose state, gets male silkworm moths spirit immersion clathrate, and drying is pulverized, and gets fine powder A;
(3). get Radix Ginseng Rubra, Cordyceps, Fructus Lycii, Semen Juglandis, Fructus Schisandrae Chinensis, Radix Polygoni Multiflori Preparata, Gecko, Herba Cistanches (system), Hippocampus by above-mentioned weight ratio, alcohol extraction, merge extractive liquid, filters, and gets liquor C;
(4). get Fructus Mori, Herba Epimedii (system), Semen Astragali Complanati by above-mentioned weight ratio and decoct with water, filter, filtrate D, be concentrated into clear paste, cooling adds ethanol, stir, leave standstill, filter, get filtrate F, filtrate F and C are merged, reclaim ethanol and be concentrated into thick paste, be dried to dried cream, dried cream powder is broken, get fine powder B;
(5). two kinds of fine powders mixing of above-mentioned A, B had both been got active constituents of medicine of the present invention.
6. a kind of preparation method of Chinese medicine for the treatment of insufficiency of kidney-YANG according to claim 5 is characterized in that the active constituents of medicine in the described step (5) is added the granule right amount of auxiliary materials, and mixing is granulated, and drying promptly gets granule.
7. a kind of preparation method of Chinese medicine for the treatment of insufficiency of kidney-YANG according to claim 5, it is characterized in that mixing with adding tablet adjuvant commonly used in the active constituents of medicine in the described step (5), tabletting is made tablet, also can not add adjuvant and directly active constituents of medicine be made tablet.
8. a kind of preparation method of Chinese medicine for the treatment of insufficiency of kidney-YANG according to claim 5, it is characterized in that fine powder A, B in the described step (5) mixes after, add lubricant or do not add, in incapsulating, capsule.
9. a kind of preparation method of Chinese medicine for the treatment of insufficiency of kidney-YANG according to claim 5 is characterized in that adding 65% alcohol reflux secondary in described the 3rd step, adds 10 times of amounts for the first time, extracted 2 hours, for the second time add 8 times of amounts, extracted 2 hours, merge extracted twice liquid.
10. a kind of preparation method of Chinese medicine for the treatment of insufficiency of kidney-YANG according to claim 5, last medicinal residues mix when it is characterized in that will getting liquor C and filtrate D in described (3) step and (4) step, decoct with water, and get filtrate E, filtrate D and E are merged, carry out downwards by described in (4).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410021412XA CN1238024C (en) | 2004-03-17 | 2004-03-17 | Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410021412XA CN1238024C (en) | 2004-03-17 | 2004-03-17 | Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1562337A true CN1562337A (en) | 2005-01-12 |
| CN1238024C CN1238024C (en) | 2006-01-25 |
Family
ID=34479810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410021412XA Expired - Fee Related CN1238024C (en) | 2004-03-17 | 2004-03-17 | Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1238024C (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100341562C (en) * | 2005-08-17 | 2007-10-10 | 秦杰 | Health caring wine for strengthening kidney and enhancing energy |
| CN100342896C (en) * | 2005-07-15 | 2007-10-17 | 王家军 | Compounding liniment contg. traditional Chinese medicine and Western medicine for treating hoary hair |
| CN102139017A (en) * | 2011-04-11 | 2011-08-03 | 乔晓峰 | Raw materials of kidney tonifying spirits, kidney tonifying spirits and preparation method of kidney tonifying spirits |
| CN102872267A (en) * | 2012-10-12 | 2013-01-16 | 绿之韵生物工程集团有限公司 | Traditional Chinese medicine composition for resisting fatigue and tonifying kidney, and preparation method thereof |
| CN103316159A (en) * | 2013-05-20 | 2013-09-25 | 缪长法 | Traditional Chinese medicine used for treating kidney deficiency, and preparation method thereof |
| CN104069265A (en) * | 2014-07-15 | 2014-10-01 | 董宝珍 | Traditional Chinese medicine wine for treating impotence and preparation method thereof |
| CN105343319A (en) * | 2015-11-20 | 2016-02-24 | 王立鑫 | Health preserving pill with kidney tonifying and qi benefiting efficacy |
| CN105998716A (en) * | 2016-07-26 | 2016-10-12 | 李厚建 | Traditional Chinese medicine composition for treating impotence |
| CN103340405B (en) * | 2013-07-11 | 2017-07-28 | 陕西大志药业有限公司 | A kind of health food for relieving physical fatigue and preparation method thereof |
| CN117599132A (en) * | 2023-10-17 | 2024-02-27 | 王顺祥 | An advanced brain-tonifying, body-building and health-care medicine and its preparation method |
-
2004
- 2004-03-17 CN CNB200410021412XA patent/CN1238024C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100342896C (en) * | 2005-07-15 | 2007-10-17 | 王家军 | Compounding liniment contg. traditional Chinese medicine and Western medicine for treating hoary hair |
| CN100341562C (en) * | 2005-08-17 | 2007-10-10 | 秦杰 | Health caring wine for strengthening kidney and enhancing energy |
| CN102139017A (en) * | 2011-04-11 | 2011-08-03 | 乔晓峰 | Raw materials of kidney tonifying spirits, kidney tonifying spirits and preparation method of kidney tonifying spirits |
| CN102139017B (en) * | 2011-04-11 | 2012-12-12 | 乔晓峰 | Raw materials of kidney tonifying spirits, kidney tonifying spirits and preparation method of kidney tonifying spirits |
| CN102872267A (en) * | 2012-10-12 | 2013-01-16 | 绿之韵生物工程集团有限公司 | Traditional Chinese medicine composition for resisting fatigue and tonifying kidney, and preparation method thereof |
| CN103316159A (en) * | 2013-05-20 | 2013-09-25 | 缪长法 | Traditional Chinese medicine used for treating kidney deficiency, and preparation method thereof |
| CN103316159B (en) * | 2013-05-20 | 2016-02-24 | 缪长法 | A kind of Chinese medicine for the treatment of deficiency of the kidney and preparation method thereof |
| CN103340405B (en) * | 2013-07-11 | 2017-07-28 | 陕西大志药业有限公司 | A kind of health food for relieving physical fatigue and preparation method thereof |
| CN104069265A (en) * | 2014-07-15 | 2014-10-01 | 董宝珍 | Traditional Chinese medicine wine for treating impotence and preparation method thereof |
| CN105343319A (en) * | 2015-11-20 | 2016-02-24 | 王立鑫 | Health preserving pill with kidney tonifying and qi benefiting efficacy |
| CN105998716A (en) * | 2016-07-26 | 2016-10-12 | 李厚建 | Traditional Chinese medicine composition for treating impotence |
| CN117599132A (en) * | 2023-10-17 | 2024-02-27 | 王顺祥 | An advanced brain-tonifying, body-building and health-care medicine and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1238024C (en) | 2006-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1233387C (en) | Chinese compound medicine for treating anhypnosis and its preparation metod | |
| CN1238024C (en) | Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method | |
| CN1263494C (en) | Granule for treating puerperal galactozemia and its preparation method | |
| CN1191082C (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1212141C (en) | Application of Atractylodes Atractylodes Oil in the Preparation of Drugs for Treating Osteoporosis | |
| CN1048877C (en) | Medicine with intelligence increasing and brain tonic function | |
| CN1634463A (en) | Medicine for treating diabetes and production method thereof | |
| CN1258372C (en) | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method | |
| CN1290529C (en) | Medicine for treating gout, hyperuricemia and hyperlipemia and preparation method thereof | |
| CN1562113A (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN1194743C (en) | Chinese medicinal composition for treating atrophic arthritis, preparing method and quality controlling method thereof | |
| CN1593482A (en) | Medicine for treating hypomnesis of middle aged and old man and its preparation process | |
| CN1042395C (en) | Queen ant extrat oral liquid and its preparation method | |
| CN1562114A (en) | Medicine for treating chronic prostatitis and its preparing method | |
| CN1660259A (en) | Chinese traditional medicine for treating imitable bowel syndrome and preparation method | |
| CN1197611C (en) | Medicine for curing choleithiasis and preparing method thereof | |
| CN1235841C (en) | Method for preparing extract of peanut leaf | |
| CN1240414C (en) | Prepared Chinese medicine for improving function of female ovary as well as preparation method and application in pharmacy | |
| CN101036722A (en) | Health-caring food for easing and improving climacteric Syndrome of men and the preparation thereof | |
| CN100337665C (en) | Oral medicine for treating diabetes | |
| CN1831015A (en) | Process for extracting fructus ligustri lucidi and Radixa stragali polysaccharide, the products and application thereof | |
| CN1634496A (en) | A kind of traditional Chinese medicine composition for treating diabetes and preparation method thereof | |
| CN1733089A (en) | Medicine for treating diabetes and complications and preparation method thereof | |
| CN1314415C (en) | Skin disease treating Chinese traditional medicine | |
| CN1709274A (en) | New application of pharmaceutical preparations with improved brain metabolism to prevent and treat osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060125 Termination date: 20160317 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |